To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Hony Capital to privatise US-listed pharma company
The Beijing-based firm joins a consortium of investors taking private Chinese pharmaceutical company Simcere in a deal worth close to $500m.
